Basilea Receives Marketing Authorization For Toctino In Switzerland

Basilea Pharmaceutica (Basilea) has reported that Toctino (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Swiss regulatory authority Swissmedic.

Reportedly, Toctino was developed by Basilea. Swissmedic approved Toctino for the use in adults who have severe refractory chronic hand eczema that is unresponsive to at least 4 weeks of extended topical treatment. The initial treatment includes the avoidance of contact to the causative irritant/noxa, skin protection and potent topical corticosteroids.

Anthony Man, CEO of Basilea, said: “We are delighted that Basilea drug received marketing authorisation in our home market. Toctino is the licensed treatment for patients suffering from severe chronic hand eczema who do not respond to potent steroid therapy. We look forward to bring Toctino to patients and physicians in Switzerland soon.”